Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Retained Earnings (2016 - 2025)

International Stem Cell (ISCO) has disclosed Retained Earnings for 16 consecutive years, with -$110.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Retained Earnings changed 0.09% to -$110.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$110.8 million, a 0.09% change, with the full-year FY2024 number at -$110.7 million, changed 0.19% from a year prior.
  • Retained Earnings was -$110.8 million for Q3 2025 at International Stem Cell, roughly flat from -$110.8 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$109.5 million in Q2 2021 to a low of -$110.9 million in Q1 2025.
  • A 5-year average of -$110.3 million and a median of -$110.4 million in 2022 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: fell 2.76% in 2021, then rose 0.33% in 2023.
  • International Stem Cell's Retained Earnings stood at -$110.0 million in 2021, then decreased by 0.3% to -$110.3 million in 2022, then fell by 0.12% to -$110.5 million in 2023, then decreased by 0.19% to -$110.7 million in 2024, then decreased by 0.1% to -$110.8 million in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Retained Earnings are -$110.8 million (Q3 2025), -$110.8 million (Q2 2025), and -$110.9 million (Q1 2025).